Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.
Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Moro-Sibilot D, Goldwasser F, Silva CAC, Terrisse S, Bonvalet M, Scherpereel A, Pegliasco H, Richard C, Ghiringhelli F, Elkrief A, Desilets A, Blanc-Durand F, Cumbo F, Blanco A, Boidot R, Chevrier S, Daillère R, Kroemer G, Alla L, Pons N, Le Chatelier E, Galleron N, Roume H, Dubuisson A, Bouchard N, Messaoudene M, Drubay D, Deutsch E, Barlesi F, Planchard D, Segata N, Martinez S, Zitvogel L, Soria JC, Besse B. Derosa L, et al. Among authors: friard s. Nat Med. 2022 Feb;28(2):315-324. doi: 10.1038/s41591-021-01655-5. Epub 2022 Feb 3. Nat Med. 2022. PMID: 35115705 Free PMC article.
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.
Molinier O, Besse B, Barlesi F, Audigier-Valette C, Friard S, Monnet I, Jeannin G, Mazières J, Cadranel J, Hureaux J, Hilgers W, Quoix E, Coudert B, Moro-Sibilot D, Fauchon E, Westeel V, Brun P, Langlais A, Morin F, Souquet PJ, Girard N. Molinier O, et al. Among authors: friard s. ESMO Open. 2022 Feb;7(1):100353. doi: 10.1016/j.esmoop.2021.100353. Epub 2021 Dec 23. ESMO Open. 2022. PMID: 34953398 Free PMC article.
Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.
Cadranel J, Cortot AB, Lena H, Mennecier B, Do P, Dansin E, Mazieres J, Chouaid C, Perol M, Barlesi F, Robinet G, Friard S, Thiberville L, Audigier-Valette C, Vergnenegre A, Westeel V, Slimane K, Buturuga A, Moro-Sibilot D, Besse B. Cadranel J, et al. Among authors: friard s. ERJ Open Res. 2018 Feb 13;4(1):00058-2017. doi: 10.1183/23120541.00058-2017. eCollection 2018 Jan. ERJ Open Res. 2018. PMID: 29450203 Free PMC article.
Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.
Loubière S, Drezet A, Beau-Faller M, Moro-Sibilot D, Friard S, Wislez M, Blons H, Daniel C, Westeel V, Madroszyk A, Léna H, Merle P, Mazières J, Zalcman G, Lacave R, Antoine M, Morin F, Missy P, Barlesi F, Auquier P, Cadranel J; French Cooperative Thoracic Intergroup (IFCT). Loubière S, et al. Among authors: friard s. Eur Respir J. 2018 Mar 15;51(3):1701467. doi: 10.1183/13993003.01467-2017. Print 2018 Mar. Eur Respir J. 2018. PMID: 29545318 Free article.
High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study.
Baldacci S, Figeac M, Antoine M, Descarpentries C, Kherrouche Z, Jamme P, Copin MC, Tulasne D, Nanni I, Beau-Faller M, Melaabi S, Levallet G, Quoix E, Moro-Sibilot D, Friard S, Missy P, Barlesi F, Cadranel J, Cortot AB. Baldacci S, et al. Among authors: friard s. J Thorac Oncol. 2020 Jan;15(1):120-124. doi: 10.1016/j.jtho.2019.09.196. Epub 2019 Oct 9. J Thorac Oncol. 2020. PMID: 31605799 Free article.
Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer.
Trédaniel J, Barlési F, Le Péchoux C, Lerouge D, Pichon É, Le Moulec S, Moreau L, Friard S, Westeel V, Petit L, Carré O, Guichard F, Raffy O, Villa J, Prévost A, Langlais A, Morin F, Wislez M, Giraud P, Zalcman G, Mornex F; French Cooperative Thoracic Intergroup (IFCT). Trédaniel J, et al. Among authors: friard s. Cancer Radiother. 2022 Sep;26(5):670-677. doi: 10.1016/j.canrad.2021.12.005. Epub 2022 Mar 5. Cancer Radiother. 2022. PMID: 35260342 Free article. Clinical Trial.
[Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours].
Meyer G, Besse B, Friard S, Girard P, Corbi P, Azarian R, Monnet I, Alifano M, Chouaid C, Descourt R, Dennewald G, Taillade L, De Luca K, Giraud F, Pichon E, Chatellier G. Meyer G, et al. Among authors: friard s. Rev Mal Respir. 2011 May;28(5):654-9. doi: 10.1016/j.rmr.2011.03.015. Epub 2011 Apr 29. Rev Mal Respir. 2011. PMID: 21645836 Clinical Trial. French.
Cannabis use and lung cancer: time to stop overlooking the problem?
Betser L, Glorion M, Mordant P, Caramella C, Ghigna MR, Besse B, Planchard D, Le Pavec J, Chapelier A, Friard S, Gounant V, Castier Y, Levy A, Mercier O, Fabre D, Fadel E, Pradere P. Betser L, et al. Among authors: friard s. Eur Respir J. 2021 May 20;57(5):2004132. doi: 10.1183/13993003.04132-2020. Print 2021 May. Eur Respir J. 2021. PMID: 33509956 Free article. No abstract available.
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.
Meyer G, Besse B, Doubre H, Charles-Nelson A, Aquilanti S, Izadifar A, Azarian R, Monnet I, Lamour C, Descourt R, Oliviero G, Taillade L, Chouaid C, Giraud F, Falcoz PE, Revel MP, Westeel V, Dixmier A, Tredaniel J, Dehette S, Decroisette C, Prevost A, Pichon E, Fabre E, Soria JC, Friard S, Stern JB, Jabot L, Dennewald G, Pavy G, Petitpretz P, Tourani JM, Alifano M, Chatellier G, Girard P. Meyer G, et al. Among authors: friard s. Eur Respir J. 2018 Oct 4;52(4):1801220. doi: 10.1183/13993003.01220-2018. Print 2018 Oct. Eur Respir J. 2018. PMID: 30262574 Free article. Clinical Trial.
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Mehlman C, Cadranel J, Rousseau-Bussac G, Lacave R, Pujals A, Girard N, Callens C, Gounant V, Théou-Anton N, Friard S, Trédaniel J, Blons H, Dujon C, Duchemann B, Schischmanoff PO, Chinet T, Giroux Leprieur E. Mehlman C, et al. Among authors: friard s. Lung Cancer. 2019 Nov;137:149-156. doi: 10.1016/j.lungcan.2019.09.019. Epub 2019 Sep 28. Lung Cancer. 2019. PMID: 31600593
43 results